Item 7.01 Regulation FD Disclosure.

On June 24, 2009, ULURU Inc., a Nevada corporation (the "Company"), announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales ("York"), have been terminated. The Company had previously announced that it intended to proceed with an offer to acquire all of the issued share capital of York, as described in that certain non-binding offer letter dated April 6, 2009 by and between the Company and York. The Company delivered written notice of the termination of such discussions to York on June 19, 2009 (the "Notice"). Also included in the Notice was notification to York that all amounts owing to the Company under that certain secured revolving credit facility established pursuant to that certain Note Purchase Agreement dated March 31, 2009 by and between the Company and York (the "Facility"), which amounts total US$1,000,000, plus all accrued but unpaid interest, are due and payable in accordance with the terms of the Facility. This Facility is secured by substantially all of the assets of York and its subsidiaries.

A copy of a press release issued by the Company regarding the items described above is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.